Trials / Completed
CompletedNCT02556788
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,212 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD5789 (trifarotene) 50µg/g Cream | CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks. |
| DRUG | Placebo Cream | Placebo cream applied once daily during 12 weeks. |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2017-02-07
- Completion
- 2017-05-12
- First posted
- 2015-09-22
- Last updated
- 2019-11-12
- Results posted
- 2019-09-03
Locations
81 sites across 8 countries: United States, Czechia, Hungary, Poland, Romania, Russia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT02556788. Inclusion in this directory is not an endorsement.